Chasing the KRAS field, Quanta Therapeutics bags $50M for two 2024 clinical trials
Quanta Therapeutics will bring its KRAS inhibitors into the clinic next year with a fresh heap of $50.7 million from blue …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
